Examples of using Astrazeneca in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
AstraZeneca(AZN)- 18 out of 18 fund managers have it- 4.47% yield at around 16/08/2017.
Three pharmaceutical companies, Merck-Frosst, Pfizer and AstraZeneca, are investing $1 million per year in the consortium.
AstraZeneca followed the trend and adopted a new RD strategy in 2010.
You can use this form to report anadverse event you have experienced whilst taking an AstraZeneca product.
AstraZeneca, which had three RD centres in Sweden, followed the trend and adopted a new RD strategy in 2010.
Nolvadex, officially known as Tamoxifen Citrate,was first developed in 1961 by ICI now AstraZeneca under the trade name Nolvadex.
AstraZeneca AB and AstraZeneca plc lodged an appeal before the Court of Justice to have that judgment of the General Court set aside.
Our portfolio includes products from well known manufacturers as Pfizer, Roche, Novartis,GSK, AstraZeneca, Vifor, Sanofi-Aventis, MSD, Sandoz, Mepha-Teva and many others.
DESCRIPTION: Zomigon(Zolmitriptan) from AstraZeneca is used for treating acute migraine headaches with or without aura(flashing lights, wavy lines, dark spots) in adults.
We are in near collaboration with all major pharmaceutical manufactuers and distributors such as Pfizer, Bayer, Roche,Novartis, AstraZeneca, MSD, Janssen-Cilag, Takeda, Sanofi-Aventis and many others.
AstraZeneca AB and AstraZeneca plc belong to a pharmaceutical group(‘AZ') which is active worldwide in the sector of the invention, development and marketing of pharmaceutical products.
And of developing nervous cell damages- as well as the danger of the Guillan-Barré syndrome, video 1 and video 2, is incomprehensible,since there is the alternative of nasal vaccination with AstraZenecás MedImmune.
By way of example, the Commission sanctioned AstraZeneca for misusing the regulatory system in order to delay market entry of generic drugs competing with its blockbuster product Losec.
After investigation of the evidence including internal company documents obtained at the company's premises in the UK and in Sweden in February 2000-the Commission has come to the preliminary conclusion that AstraZeneca may have infringed Article 82 of the EU Treaty and Article 54 of the EEA Agreement.
AstraZeneca plc and AstraZeneca AB brought an action before the Court for annulment of the Commission's decision or, at the very least, for a reduction of the fines imposed.
The survey was co-developed by an advisory panel of leading industry experts from AstraZeneca, Clinical Supplies Management, FibroGen, GlaxoSmithKline, OPKO Biologics, PCI Pharma Services, QuickStat Global Life Science Logistics and Sunovion Pharmaceuticals.
AstraZeneca is the owner of European patent 1020461, which had been revoked by an EPO opposition division for lack of inventive step; on appeal, however, it had been maintained in amended form by the board of appeal T1677/11.
For example, Thermo Fisher Scientific, which is one of the leading instrument and reagent providers,partnered with AstraZeneca and provided them with RNA-guide libraries that target individual gene families and human genes in order identify new biological targets.
Example: AstraZeneca conducted a clinical study exploring the question:"Can a stress test as a quasi anxiety-inducing situation show, whether a substance reduces anxiety?" If this were the case, the substance's therapeutic effectiveness?
Celera Genomics, one of the leadingsuppliers of genetic information in addition to AstraZeneca has signed contracts for using products and platforms from Virtual Genetics Laboratory AB for Information Retrieval, text mining, data selection, annotation and representation of complex biological data.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.
According to the evidence in the Commission's possession, AstraZeneca concealed from these patent offices the date at which it received its first marketing authorisation for Losec, thereby enabling AstraZeneca to obtain extra protection for Losec in certain countries.
AstraZeneca, United Kingdom BeschaffungsService, Austria Biganos EIG, France Bongard, France Electrabel, Belg um Fiskars, Finland The Health and Safety Executive, United Kingdom IKA, Denmark König+ Neurath, Germany Linjebus, Denmark Ministry for Employment and Labour, Belgium Nokia, Sweden Polytop, Germany Renault Technocenter, France Rockfon, Denmark Smurfit- Cellulose du Pin, France Texaco, United Kingdom TCO, Sweden VCA, Netherlands National Working Environment Authority, Denmark Representatives from Øresundskonsortiet, Denmark.
As part of the marketing authorisation for rosuvastatin within Europe, AstraZeneca committed to apply for a 5-mg dose of rosuvastatin together with any necessary variations within 12 months of completion of the Mutual Recognition Process for the 10 mg, 20 mg and 40 mg formulations.
Within the framework of the AstraZeneca case(see Box 2 below) and in parallel to it, the Competition DG has become aware of potentially anticompetitive behaviour aimed at excluding or delaying generic competition.
Cancer Research UK and AstraZeneca have announced today(Monday) that they are opening a new center in the UK, dedicated to realizing the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.
Decision fining the AstraZeneca company for misusing of regulatory system: The Commission adopted a new approach to interpreting Article 82(EC) when it fined AstraZeneca AB and AstraZeneca Plc(AZ) EUR 60 million for breach of Article 82 EC and Article 54 of the European Economic Area Treaty.
On 15 June, the Commission adopted a decision fining AstraZeneca AB and AstraZeneca Plc(AZ) EUR 60 million for having infringed Article 82 EC and Article 54 EEA by misusing public procedures and regulations in a number of EEA States with a view to excluding generic firms and parallel traders from competing against AZ's anti‑ulcer product Losec47.